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impression smears and lung tissue sections were made
and stained to observe the extent of infection. Also, the
samples of lung tissue were observed with transmission
electron microscopy for morphology study. Genomic DNA
was extracted from the lung tissue of the infected animals.
5.8S and ITS1 and ITS2 regions of the rDNA, a portion of
the mitochondrial large subunit (mtLS) rDNA and entire
fragment of 18S rRDA were ampliﬁed and sequenced. The
sequences were compared with those from other isolates of
pneumocystis and those from fungal out groups accessed in
GenBank. Phylogenetic trees based on the sequences were
constructed with Neighbor-joining (NJ) method.
Results: The current study showed that dexamethasone
immunosuppression consistently resulted in histologically
apparent lung infection in gerbils (28/35). Analysis of the
Sequences and phylogenetic trees demonstrated that the
gerbil Pneumocystis grouped with, but was distinct from
other rodent Pneumocystis.
Our results suggest that the gerbil Pneumocystis is distinct
enough from the Pneumocystis species from in other
rodents to consider it as a separate species. According
to the criteria recommended in 2006 (Redhead et al,
2006), the appropriate species name would be Pneumocystis
unguiculatii.
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Aim: To investigate the proteomic proﬁle of CSF in patients
with active cysticercosis with that of healthy subjects in
order to further search the potential biomarkers related to
neurocysticercosis.
Methods: 2D-DIGE (two-dimensional difference in-gel
electrophoresis) was used to investigate differential
expressed proteins in CSF of patients with active
neurocysticercosis by comparing the protein proﬁle of
pooled CSF from patients with active neurocysticercosis and
healthy subjects respectively. The Coomassie blue stained
protein spots correspondent to the differentially expressed
protein spots in DIGE analysis gel were excised and identiﬁed
with MALDI-TOF-TOF.
Results: Analysis of 2D-DIGE with DeCyder 5.0 software
found 94 protein spots were differentially expressed over
1.5 fold between active neurocysticercosis group and
control group. Forty four of enzyme digested peptide
mass ﬁngerprint were obtained with MALDI-TOF-TOF. Of
the 44 proteins, 23 were identiﬁed through search of
the NCBI protein database with Mascot software, including
19 expressed more than 1.5-fold higher and 4 expressed
more than 1.5-fold lower in CSF of patients with active
neurocysticercosis.
Conclusions: Our approach demonstrates the capacity of
proteome approach to analyze cysticercosis at the level
of CSF proteins and provides a rational basis for screening
biomarkers that may be used for the study of diagnosis
of active neurocysticercosis. Further studies are needed
to conﬁrm this observation and determine characteristic
proteomic proﬁle or potential biomarker.
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We have successfully developed an immunocompetent
mouse model for the tolerance of human hepatitis B
virus persistence (Huang et al., PNAS 2006; 103: 17862)
using a replication-competent plasmid, pAAV/HBV1.2. By
this model, we recently found that mice receiving c/e-
null pAAV/HBV1.2, which is defective both in core and e
antigen expression, had higher surface antigen persistence
rate compared to those receiving wild type (100% and
14 20% respectively at 8 weeks post-injection). On the
other hand, mice receiving e-null pAAV/HBV1.2 developed
similar surface antigen persistence rate to mice receiving
wild type. To dissect which domain, the assembly domain
(aa 1 149) and/or the protamine-like domain (aa 150 185),
of core protein is important for the HBsAg persistence,
we generated a series of core protein mutants in
pAAV/HBV1.2 by site-directed mutagenesis. Wild-type and
the mutant c/e-null, HBc118, HBc150, HBc166, and HBc175
pAAV/HBV1.2 were hydrodynamically injected into C57BL/6
mice respectively and the persistence of HBsAg as well
as the viral transcription and translation were assayed in
these mice. At day 3 and 41 post injection, the levels of
all viral transcripts were similar among mice receiving the
mutants and wild type, while the viral replication could
only be detected in mice receiving wild type and HBc175
mutant. Interestingly, mice injected with HBc166 and
HBc175 mutants, in which the protamine-like domain of core
protein are partially deleted, showed signiﬁcantly higher
HBsAg persistence rate (86 100% and 71 83 respectively)
than mice injected with wild type at 8 weeks post-injection.
In mice receiving HBc118 and HBc150 mutants, core proteins
were barely detected and the HBsAg persistence rates in
these mice were close to that in mice receiving the c/e-null
mutant. Our preliminary data suggested that protamine-
like domain, especially the carboxyl-terminal 10-aa region,
might be important for HBsAg persistence. The underlying
mechanisms for these phenomena are under investigation.
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Chronic hepatitis B is a major cause of liver-related death
worldwide. Interleukin-12 (IL-12) induction accompanies
viral clearance in chronic hepatitis B virus (HBV) infection.
Here, we tested the therapeutic potential of Interleukin-12
(IL-12) gene therapy in woodchucks with chronic woodchuck
hepatitis virus (WHV) infection, a condition that closely
resembles chronic hepatitis B. Woodchucks were treated
by intrahepatic injection of a helper-dependent adenoviral
vector encoding IL-12 under the control of a liver-speciﬁc
RU486-responsive promoter. All woodchucks with viral load
below 1010 viral genomes (vg)/ml showed a marked and
sustained reduction of viremia accompanied by a reduction
in hepatic WHV-DNA, loss of e- and surface antigens
and improved liver histology. In contrast, none of the
woodchucks with viremia higher than 1010 vg/ml responded
to therapy. In the responder animals, the antiviral effect
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was associated with induction of T-cell immunity against
viral antigens and reduction of hepatic expression of Foxp3.
Studies performed to elucidate the rational behind the lack
of antiviral activity of IL-12 in animals with high viremia
showed that the presence of high amounts of WHV-DNA in
serum is associated with the absence of IL-12-responsiveness
in vitro. In conclusion, IL-12-based gene therapy is an
efﬁcient approach to treat chronic hepadnavirus infection
in all cases with viral load below 1010 vg/ml, which is the
situation of most patients with chronic hepatitis B. The
elucidation of the precise mechanisms responsible for the
lack of response to IL-12 in animals with high viral load
will be important for the development of more efﬁcient
therapies against chronic hepatitis infection.
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Persistent viral infection in liver is still a global threat to
human health. It has been suggested that compromised
immune responses play a critical role for chronic viral
infection. It is, at least in part, shown that impaired
innate and adaptive immunity as well as liver tolerance
are responsible for the compromised immune responses,
but the underlying cellular and molecular mechanisms
remain largely undeﬁned. Recent studies have suggested
that CD4+CD25+ regulatory T-cells (Treg) are increased and
linked to compromised immune responses in patients with
hepatocellular carcinoma (HCC). This study attempts to
further characterize CD4+CD25+FoxP3+ Treg in blood, tumor
and non-tumor liver tissues of HCC patients, and understand
how the Treg affect immune responses and contribute
to disease progression. One-hundred and nineteen HCC
patients with chronic hepatitis B virus (HBV) infection
(designated as HBV-related HCC patients), 21 HBV-related
liver cirrhosis (LC) patients, and 47 normal controls
were enrolled. Flow cytometric, immunohistochemical, and
immunosuppressive assays were employed for analyses of
property of Treg. Multivariate analysis of prognostic factors
for overall survival was made using Cox’s proportional
hazards model. Circulating CD4+CD25+FoxP3+ Treg frequency
was signiﬁcantly increased and correlated with disease
progression in HCC patients. An abundant accumulation
of Treg concurrent with signiﬁcantly reduced inﬁltration of
CD8+ T-cells was found in tumor regions compared with non-
tumor regions. Granzyme A, B and perforin expressions were
dramatically decreased in tumor-inﬁltrating CD8+ T-cells.
Furthermore, Treg of HCC patients inhibited proliferation,
activation, degranulation, and production of Granzyme A,
B and perforin of CD8+ T-cells induced by anti-CD3/CD28
antibodies. Importantly, increased numbers of circulating
Treg were associated with high mortality and reduced
survival time of HCC patients.
Conclusion: Increased CD4+CD25+FoxP3+ Treg may impair
CD8+ T-cell function, promote disease progression and
represent both a potential prognostic marker and a
therapeutic target for HBV-related HCC individuals.
